Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions
Open Access
- 28 May 2014
- journal article
- research article
- Published by Hindawi Limited in Advances in Urology
- Vol. 2014, 1-6
Abstract
Objectives. Level 1 evidence supports the use of neoadjuvant chemotherapy (NAC) to improve overall survival in muscle invasive bladder cancer; however utilization rates remain low. The aims of our study were to determine factors associated with NAC use, to more clearly define reasons for low utilization, and to determine the current rate of NAC use among urologic oncologists.Materials and Methods. Active members of the Society for Urologic Oncology were provided a 20-question survey. Descriptive statistical analysis was conducted for each question and univariate analysis was performed.Results. We achieved a response rate of 21%. Clinical T3/T4 disease was the most often selected reason for recommending NAC (87%). Concerns with recommending NAC were age and comorbidities (54%) followed by delay in surgery (35%). An association was identified between urologic oncologists who discussed NAC with >90% of their patients and medical oncologists “always” recommending NAC (). NAC utilization rate was between 30 and 57%.Conclusions. Amongst this highly specialized group of respondents, clinical T3-T4 disease was the most common reason for implementation of NAC. Respondents who frequently discussed NAC were more likely to report their medical oncologist always recommending NAC. Reported NAC use was higher in this surveyed group (30–57%) compared with recently published rates.
Keywords
This publication has 21 references indexed in Scilit:
- ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinoma—Neoadjuvant and Adjuvant SettingsEuropean Urology, 2013
- A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder CancerEuropean Urology, 2012
- Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completionIndian Journal of Urology, 2012
- International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 TrialJournal of Clinical Oncology, 2011
- Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle‐invasive bladder cancerCancer, 2011
- Treatment of Muscle Invasive Bladder Cancer: Evidence From the National Cancer Database, 2003 to 2007Journal of Urology, 2011
- Contemporary use of perioperative cisplatin‐based chemotherapy in patients with muscle‐invasive bladder cancerCancer, 2010
- Cystectomy Delay More Than 3 Months From Initial Bladder Cancer Diagnosis Results in Decreased Disease Specific and Overall SurvivalJournal of Urology, 2006
- Delaying Radical Cystectomy for Muscle Invasive Bladder Cancer Results in Worse Pathological StageJournal of Urology, 2003
- Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder CancerNew England Journal of Medicine, 2003